Publications by authors named "Nuka Benz"

The flavivirus genus includes human pathogenic viruses such as Dengue (DENV), West Nile (WNV) and Zika virus (ZIKV) posing a global health threat due to limited treatment options. Host ion channels are crucial for various viral life cycle stages, but their potential as targets for antivirals is often not fully realized due to the lack of selective modulators. Here, we observe that treatment with ML2-SA1, an agonist for the human endolysosomal cation channel TRPML2, impairs ZIKV replication.

View Article and Find Full Text PDF

Zoonoses such as ZIKV and SARS-CoV-2 pose a severe risk to global health. There is urgent need for broad antiviral strategies based on host-targets filling gaps between pathogen emergence and availability of therapeutic or preventive strategies. Significant reduction of pathogen titers decreases spread of infections and thereby ensures health systems not being overloaded and public life to continue.

View Article and Find Full Text PDF
Article Synopsis
  • Escape mutations in the spike protein of SARS-CoV-2 contribute significantly to breakthrough infections caused by the Omicron variant, resulting in low levels of neutralizing antibodies after initial vaccinations.
  • Booster vaccinations, specifically the fourth shot of the monovalent RNA vaccine (Spikevax), increase antibody levels against the Omicron variant, but these levels diminish back to very low titers after six months.
  • Both the Omicron and Delta variants show a decrease in neutralizing capacity over time post-vaccination, with Omicron exhibiting lower overall antibody levels, indicating that the fourth dose does not improve the waning immunity or broaden the antibody response.
View Article and Find Full Text PDF

Waning immunity against SARS-CoV-2 and the emergence of variants, especially of the most distant variant, Omicron, affect titers of neutralizing antibodies in the sera of vaccinated individuals. Thus, two vaccinations with the mRNA vaccine BNT162b fail to induce neutralizing antibodies against the Omicron variant. A first booster vaccination increases Omicron-RBD-binding IgG and IgA and neutralizing capacity.

View Article and Find Full Text PDF
Article Synopsis
  • Omicron has rapidly spread globally, leading to increased infections even in highly vaccinated populations, necessitating an analysis of antibody responses in vaccinated individuals.
  • Sera from individuals vaccinated with vector vaccines (like AZ and J&J) showed minimal neutralization against Omicron, whereas those with mRNA or mixed vaccine regimens displayed weak but measurable responses.
  • A booster dose of the mRNA vaccine significantly enhanced antibody levels and neutralization capacity against various SARS-CoV-2 variants, highlighting the need for mRNA vaccines in effective vaccination strategies.
View Article and Find Full Text PDF

In light of an increasing number of vaccinated and convalescent individuals, there is a major need for the development of robust methods for the quantification of neutralizing antibodies; although, a defined correlate of protection is still missing. Sera from hospitalized COVID-19 patients suffering or not suffering from acute respiratory distress syndrome (ARDS) were comparatively analyzed by plaque reduction neutralization test (PRNT) and pseudotype-based neutralization assays to quantify their neutralizing capacity. The two neutralization assays showed comparable data.

View Article and Find Full Text PDF

Many of the approved SARS-CoV-2 vaccines are based on a stabilized variant of the spike protein. This raises the question of whether the immune response against the stabilized spike is identical to the immune response that is elicited by the native spike in the case of a SARS-CoV-2 infection. Using a peptide array-based approach, we analysed the binding of antibodies from Comirnaty-elicited, convalescent, and control sera to the peptides covering the spike protein.

View Article and Find Full Text PDF

Background: The mRNA vaccine BNT162b2 (Comirnaty, BioNTech/Pfizer) and the vaccine candidate CVnCoV (Curevac) each encode a stabilized spike protein of SARS-CoV2 as antigen but differ with respect to the nature of the mRNA (modified versus unmodified nucleotides) and the mRNA amount (30 μg versus 12 μg RNA). This study characterizes antisera elicited by these two vaccines in comparison to convalescent sera.

Methods: Sera from BNT162b2 vaccinated healthcare workers, and sera from participants of a phase I trial vaccinated with 2, 4, 6, 8, or 12 μg CVnCoV and convalescent sera from hospitalized patients were analyzed by ELISA, neutralization tests, surface plasmon resonance (SPR), and peptide arrays.

View Article and Find Full Text PDF

Background: Bacillus subtilis is widely used for the industrial production of recombinant proteins, mainly due to its high secretion capacity, but higher production yields can be achieved only if bottlenecks are removed. To this end, a crucial process is translation initiation which takes place at the ribosome binding site enclosing the Shine Dalgarno sequence, the start codon of the target gene and a short spacer sequence in between. Here, we have studied the effects of varying spacer sequence lengths in vivo on the production yield of different intra- and extracellular proteins.

View Article and Find Full Text PDF